The NIH Lipo-COVID Study: A Pilot NMR Investigation of Lipoprotein Subfractions and Other Metabolites in Patients with Severe COVID-19
Abstract
:1. Introduction
2. Methods
3. Results
3.1. Patient Characteristics
3.2. Significant Findings Detected in the Plasma of Participants
- (a)
- Lipoprotein particle numbers and size distribution
- (b)
- Other metabolites
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Kyriakidis, N.C.; López-Cortés, A.; González, E.V.; Grimaldos, A.B.; Prado, E.O. SARS-CoV-2 vaccines strategies: A comprehensive review of phase 3 candidates. NPJ Vaccines 2021, 6, 28. [Google Scholar] [CrossRef]
- Nalbandian, A.; Sehgal, K.; Gupta, A.; Madhavan, M.V.; McGroder, C.; Stevens, J.S.; Cook, J.R.; Nordvig, A.S.; Shalev, D.; Sehrawat, T.S.; et al. Post-acute COVID-19 syndrome. Nat. Med. 2021, 27, 601–615. [Google Scholar] [CrossRef]
- Lopez-Leon, S.; Wegman-Ostrosky, T.; Perelman, C.; Sepulveda, R.; Rebolledo, P.A.; Cuapio, A.; Villapol, S. More than 50 Long-term effects of COVID-19: A systematic review and meta-analysis. Sci. Rep. 2021, 11, 16114. [Google Scholar] [CrossRef]
- Huang, C.; Huang, L.; Wang, Y.; Li, X.; Ren, L.; Gu, X.; Kang, L.; Guo, L.; Liu, M.; Zhou, X.; et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet 2021, 397, 220–232. [Google Scholar] [CrossRef]
- Accili, D. Can COVID-19 cause diabetes? Nat. Metab. 2021, 3, 123–125. [Google Scholar] [CrossRef] [PubMed]
- Iacobellis, G.; Penaherrera, C.A.; Bermudez, L.E.; Mizrachi, E.B. Admission hyperglycemia and radiological findings of SARS-CoV2 in patients with and without diabetes. Diabetes Res. Clin. Pract. 2020, 164, 108185. [Google Scholar] [CrossRef] [PubMed]
- Rubino, F.; Amiel, S.A.; Zimmet, P.; Alberti, G.; Bornstein, S.; Eckel, R.H.; Mingrone, G.; Boehm, B.; Cooper, M.E.; Chai, Z.; et al. New-Onset Diabetes in Covid-19. N. Engl. J. Med. 2020, 383, 789–790. [Google Scholar] [CrossRef]
- Gianchandani, R.; Esfandiari, N.H.; Ang, L.; Iyengar, J.; Knotts, S.; Choksi, P.; Pop-Busui, R. Managing Hyperglycemia in the COVID-19 Inflammatory Storm. Diabetes 2020, 69, 2048–2053. [Google Scholar] [CrossRef]
- Ayres, J.S. A metabolic handbook for the COVID-19 pandemic. Nat. Metab. 2020, 2, 572–585. [Google Scholar] [CrossRef]
- Shalaurova, I.; Connelly, M.A.; Garvey, W.T.; Otvos, J.D. Lipoprotein Insulin Resistance Index: A Lipoprotein Particle–Derived Measure of Insulin Resistance. Metab. Syndr. Relat. Disord. 2014, 12, 422–429. [Google Scholar] [CrossRef]
- Li, Y.; Zhang, Y.; Lu, R.; Dai, M.; Shen, M.; Zhang, J.; Cui, Y.; Liu, B.; Lin, F.; Chen, L.; et al. Lipid metabolism changes in patients with severe COVID-19. Clin. Chim. Acta 2021, 517, 66–73. [Google Scholar] [CrossRef]
- Masana, L.; Correig, E.; Ibarretxe, D.; Anoro, E.; Arroyo, J.A.; Jericó, C.; Guerrero, C.; Miret, M.; Näf, S.; Pardo, A.; et al. Low HDL and high triglycerides predict COVID-19 severity. Sci. Rep. 2021, 11, 7217. [Google Scholar] [CrossRef] [PubMed]
- Roccaforte, V.; Daves, M.; Lippi, G.; Spreafico, M.; Bonato, C. Altered lipid profile in patients with COVID-19 infection. J. Lab. Precis. Med. 2021, 6, 2. [Google Scholar] [CrossRef]
- Sun, J.T.; Chen, Z.; Nie, P.; Ge, H.; Shen, L.; Yang, F.; Qu, X.L.; Ying, X.Y.; Zhou, Y.; Wang, W.; et al. Lipid Profile Features and Their Associations with Disease Severity and Mortality in Patients With COVID-19. Front. Cardiovasc. Med. 2020, 7, 584987. [Google Scholar] [CrossRef]
- Tanaka, S.; De Tymowski, C.; Assadi, M.; Zappella, N.; Jean-Baptiste, S.; Robert, T.; Peoc’H, K.; Lortat-Jacob, B.; Fontaine, L.; Bouzid, D.; et al. Lipoprotein concentrations over time in the intensive care unit COVID-19 patients: Results from the ApoCOVID study. PLoS ONE 2020, 15, e0239573. [Google Scholar] [CrossRef] [PubMed]
- Hu, X.; Chen, D.; Wu, L.; He, G.; Ye, W. Low Serum Cholesterol Level Among Patients with COVID-19 Infection in Wenzhou, China. Wenzhou Central Hospital. SSRN. 2020. Available online: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3544826 (accessed on 23 August 2021). [CrossRef]
- Garcia, E.; Bennett, D.W.; Connelly, M.A.; Jeyarajah, E.J.; Warf, F.C.; Shalaurova, I.; Matyus, S.P.; Wolak-Dinsmore, J.; Oskardmay, D.N.; Young, R.M.; et al. The extended lipid panel assay: A clinically deployed high-throughput nuclear magnetic resonance method for the simultaneous measurement of lipids and Apolipoprotein B. Lipids Health Dis. 2020, 19, 247. [Google Scholar] [CrossRef] [PubMed]
- Li, J.; Wang, X.; Chen, J.; Zuo, X.; Zhang, H.; Deng, A. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes. Metab. 2020, 22, 1935–1941. [Google Scholar] [CrossRef]
- Kanetake, J.; Kanawaku, Y.; Mimasaka, S.; Sakai, J.; Hashiyada, M.; Nata, M.; Funayama, M. The relationship of a high level of serum beta-hydroxybutyrate to cause of death. Leg. Med. 2005, 7, 169–174. [Google Scholar] [CrossRef]
- Wang, T.J.; Larson, M.; Vasan, R.S.; Cheng, S.; Rhee, E.P.; McCabe, E.; Lewis, G.D.; Fox, C.S.; Jacques, P.F.; Fernandez, C.; et al. Metabolite profiles and the risk of developing diabetes. Nat. Med. 2011, 17, 448–453. [Google Scholar] [CrossRef]
- Ballout, R.A.; Remaley, A.T. GlycA: A new biomarker for systemic inflammation and cardiovascular disease (CVD) risk assessment. J. Lab. Precis. Med. 2020, 5, 17. [Google Scholar] [CrossRef]
- Otvos, J.D.; Shalaurova, I.; Wolak-Dinsmore, J.; Connelly, M.A.; Mackey, R.H.; Stein, J.H.; Tracy, R.P. GlycA: A Composite Nuclear Magnetic Resonance Biomarker of Systemic Inflammation. Clin. Chem. 2015, 61, 714–723. [Google Scholar] [CrossRef] [Green Version]
- Jeyarajah, E.J.; Cromwell, W.; Otvos, J.D. Lipoprotein Particle Analysis by Nuclear Magnetic Resonance Spectroscopy. Clin. Lab. Med. 2006, 26, 847–870. [Google Scholar] [CrossRef] [PubMed]
- Peckham, H.; de Gruijter, N.M.; Raine, C.; Radziszewska, A.; Ciurtin, C.; Wedderburn, L.R.; Rosser, E.C.; Webb, K.; Deakin, C.T. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat. Commun. 2020, 11, 6317. [Google Scholar] [CrossRef]
- Ballout, R.A.; Kong, H.; Sampson, M.; Otvos, J.D.; Cox, A.; Agbor-Enoh, S.; Remaley, A.T. The NIH Lipo-COVID Study: A pilot NMR investigation of lipoprotein subfractions and other metabolites in patients with severe COVID-19. In ChemRxiv; Cambridge Open Engage: Cambridge, UK, 2021. [Google Scholar]
- Kostner, G.M.; Laggner, P.; Prexl, H.J.; Holasek, A. Investigation of the abnormal low-density lipoproteins occurring in patients with obstructive jaundice. Biochem. J. 1976, 157, 401–407. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bedi, S.; Garcia, E.; Jeyarajah, E.J.; Shalaurova, I.; Perez-Matos, M.C.; Jiang, Z.G.; Dullaart, R.P.F.; Matyus, S.P.; Kirk, W.J.; Otvos, J.D.; et al. Characterization of LP-Z Lipoprotein Particles and Quantification in Subjects with Liver Disease Using a Newly Developed NMR-Based Assay. J. Clin. Med. 2020, 9, 2915. [Google Scholar] [CrossRef] [PubMed]
- Ross, A.; Murphy, G.M.; Wilkinson, P.A.; Mills, G.L.; Sherlock, S. Occurrence of an abnormal lipoprotein in patients with liver disease. Gut 1970, 11, 1035–1037. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Torsvik, H.; Berg, K.; Magnani, H.N.; McConathy, W.J.; Alaupovic, P.; Gjone, E. Identification of the abnormal cholestatic lipoprotein (LP-X) in familial lecithin: Cholesterol acyltransferase deficiency. FEBS Lett. 1972, 24, 165–168. [Google Scholar] [CrossRef] [Green Version]
- Camont, L.; Lhomme, M.; Rached, F.; Le Goff, W.; Nègre-Salvayre, A.; Salvayre, R.; Calzada, C.; Lagarde, M.; Chapman, M.J.; Kontush, A. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: Relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb. Vasc. Biol. 2013, 33, 2715–2723. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Martin, S.S.; Khokhar, A.A.; May, H.; Kulkarni, K.R.; Blaha, M.J.; Joshi, P.H.; Toth, P.P.; Muhlestein, J.B.; Anderson, J.L.; Knight, S.; et al. HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: The lipoprotein investigators collaborative. Eur. Hearth J. 2015, 36, 22–30. [Google Scholar] [CrossRef] [Green Version]
- Kim, D.S.; Li, Y.K.; Bell, G.A.; Burt, A.A.; Vaisar, T.; Hutchins, P.M.; Furlong, C.E.; Otvos, J.D.; Polak, J.F.; Arnan, M.K.; et al. Concentration of Smaller High-Density Lipoprotein Particle (HDL-P) Is Inversely Correlated with Carotid Intima Media Thickening After Confounder Adjustment: The Multi-Ethnic Study of Atherosclerosis (MESA). J. Am. Hear. Assoc. 2016, 5. [Google Scholar] [CrossRef] [Green Version]
- Otvos, J.D.; Guyton, J.R.; Connelly, M.A.; Akapame, S.; Bittner, V.; Kopecky, S.L.; Lacy, M.; Marcovina, S.M.; Muhlestein, J.B.; Boden, W.E. Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial. J. Clin. Lipidol. 2018, 12, 348–355.e2. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Barter, P.J.; Nicholls, S.; Rye, K.-A.; Anantharamaiah, G.M.; Navab, M.; Fogelman, A.M. Antiinflammatory Properties of HDL. Circ. Res. 2004, 95, 764–772. [Google Scholar] [CrossRef] [PubMed]
- Chung, C.P.; Oeser, A.; Raggi, P.; Sokka, T.; Pincus, T.; Solus, J.F.; Linton, M.F.; Fazio, S.; Stein, C.M. Lipoprotein Subclasses Determined by Nuclear Magnetic Resonance Spectroscopy and Coronary Atherosclerosis in Patients with Rheumatoid Arthritis. J. Rheumatol. 2010, 37, 1633–1638. [Google Scholar] [CrossRef] [Green Version]
- Williams, P.T. Low high-density lipoprotein 3 reduces the odds of men surviving to age 85 during 53-year follow-up. J. Am. Geriatr. Soc. 2012, 60, 430–436. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Harbaum, L.; Ghataorhe, P.; Wharton, J.; Jiménez, B.; Howard, L.S.G.; Gibbs, J.S.R.; Nicholson, J.; Rhodes, C.; Wilkins, M.R. Reduced plasma levels of small HDL particles transporting fibrinolytic proteins in pulmonary arterial hypertension. Thorax 2018, 74, 380–389. [Google Scholar] [CrossRef] [Green Version]
- Malas, M.B.; Naazie, I.N.; Elsayed, N.; Mathlouthi, A.; Marmor, R.; Clary, B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine 2020, 29, 100639. [Google Scholar] [CrossRef]
- Nordestgaard, B.G. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights from Epidemiology, Genetics, and Biology. Circ. Res. 2016, 118, 547–563. [Google Scholar] [CrossRef] [PubMed]
- Chapman, M.J.; Ginsberg, H.N.; Amarenco, P.; Andreotti, F.; Borén, J.; Catapano, A.L.; Descamps, O.S.; Fisher, E.; Kovanen, P.T.; Kuivenhoven, J.A.; et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management. Eur. Hearth J. 2011, 32, 1345–1361. [Google Scholar] [CrossRef] [Green Version]
- Ossoli, A.; Neufeld, E.B.; Thacker, S.G.; Vaisman, B.; Pryor, M.; Freeman, L.A.; Brantner, C.A.; Baranova, I.; Francone, N.O. Lipoprotein X Causes Renal Disease in LCAT Deficiency. PLoS ONE 2016, 11, e0150083. [Google Scholar] [CrossRef] [Green Version]
- Zhang, C.; Shi, L.; Wang, F.-S. Liver injury in COVID-19: Management and challenges. Lancet Gastroenterol. Hepatol. 2020, 5, 428–430. [Google Scholar] [CrossRef]
- Nardo, A.D.; Schneeweiss-Gleixner, M.; Bakail, M.; Dixon, E.D.; Lax, S.F.; Trauner, M. Pathophysiological mechanisms of liver injury in COVID-19. Liver Int. 2021, 41, 20–32. [Google Scholar] [CrossRef]
- Del Valle, D.M.; Kim-Schulze, S.; Huang, H.-H.; Beckmann, N.D.; Nirenberg, S.; Wang, B.; Lavin, Y.; Swartz, T.H.; Madduri, D.; Stock, A.; et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 2020, 26, 1636–1643. [Google Scholar] [CrossRef]
- Nadim, M.K.; Forni, L.G.; Mehta, R.L.; Connor, M.J.; Liu, K.D.; Ostermann, M.; Rimmelé, T.; Zarbock, A.; Bell, S.; Bihorac, A.; et al. COVID-19-associated acute kidney injury: Consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nat. Rev. Nephrol. 2020, 16, 747–764. [Google Scholar] [CrossRef]
- Ji, P.; Zhu, J.; Zhong, Z.; Li, H.; Pang, J.; Li, B.; Zhang, J. Association of elevated inflammatory markers and severe COVID-19: A meta-analysis. Medicine 2020, 99, e23315. [Google Scholar] [CrossRef]
- Zeng, F.; Huang, Y.; Guo, Y.; Yin, M.; Chen, X.; Xiao, L.; Deng, G. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int. J. Infect. Dis. 2020, 96, 467–474. [Google Scholar] [CrossRef] [PubMed]
- Connelly, M.A.; Wolak-Dinsmore, J.; Dullaart, R.P.F. Branched Chain Amino Acids Are Associated with Insulin Resistance Independent of Leptin and Adiponectin in Subjects with Varying Degrees of Glucose Tolerance. Metab. Syndr. Relat. Disord. 2017, 15, 183–186. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ruiz-Canela, M.; Toledo, E.; Clish, C.; Hruby, A.; Liang, L.; Salas-Salvadó, J.; Razquin, C.; Corella, D.; Estruch, R.; Ros, E.; et al. Plasma Branched-Chain Amino Acids and Incident Cardiovascular Disease in the PREDIMED Trial. Clin. Chem. 2016, 62, 582–592. [Google Scholar] [CrossRef] [Green Version]
- Wolak-Dinsmore, J.; Gruppen, E.G.; Shalaurova, I.; Matyus, S.P.; Grant, R.P.; Gegen, R.; Bakker, S.J.; Otvos, J.D.; Connelly, M.A.; Dullaart, R.P. A novel NMR-based assay to measure circulating concentrations of branched-chain amino acids: Elevation in subjects with type 2 diabetes mellitus and association with carotid intima media thickness. Clin. Biochem. 2018, 54, 92–99. [Google Scholar] [CrossRef] [PubMed]
- HoleČek, M. Branched-chain amino acids in health and disease: Metabolism, alterations in blood plasma, and as supplements. Nutr. Metab. 2018, 15, 33. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Druml, W.; Heinzel, G.; Kleinberger, G. Amino acid kinetics in patients with sepsis. Am. J. Clin. Nutr. 2001, 73, 908–913. [Google Scholar] [CrossRef] [PubMed]
- Ghimire, P.; Dhamoon, A.S. Ketoacidosis. In StatPearls; NBCI: Treasure Island, FL, USA, 2021. Available online: https://www.ncbi.nlm.nih.gov/books/NBK534848/ (accessed on 25 August 2021).
- Inaba, M.; Kumeda, Y.; Yamada, S.; Toi, N.; Hamai, C.; Noguchi, K.; Yasuda, E.; Furumitsu, Y.; Emoto, M.; Ohno, Y. Association of higher arterial ketone body ratio (acetoacetate/β-hydroxybutyrate) with relevant nutritional marker in hemodialysis patients. BMC Nephrol. 2020, 21, 510. [Google Scholar] [CrossRef] [PubMed]
- Takahashi, M.; Ueda, K.; Tabata, R.; Iwata, S.; Ozawa, K.; Uno, S.; Kinoshita, M. Arterial ketone body ratio as a prognostic indicator in acute heart failure. J. Lab. Clin. Med. 1997, 129, 72–80. [Google Scholar] [CrossRef]
- Stubbs, B.J.; Koutnik, A.P.; Goldberg, E.L.; Upadhyay, V.; Turnbaugh, P.J.; Verdin, E.; Newman, J.C. Investigating Ketone Bodies as Immunometabolic Countermeasures against Respiratory Viral Infections. Med 2020, 1, 43–65. [Google Scholar] [CrossRef] [PubMed]
- Lindberg, B.R.; Videm, V.; Dahl, T.; Sørensen, G.; Fiane, A.E.; Thiara, A.S. Influence of the ECMO circuit on the concentration of nutritional supplements. Sci. Rep. 2020, 10, 19275. [Google Scholar] [CrossRef]
Parameter | Number of Patients Out of 32 (%) | |
---|---|---|
Age (yrs) | 20–30 | 2 (6.25) |
30–50 | 21 (65.6) | |
≥50 | 9 (28.1) | |
Sex | Males | 27 (84.4) |
Females | 5 (15.6) | |
BMI (kg/m2) | <25 | 3 (9.4) |
25–30 | 8 (25) | |
30–40 | 12 (37.5) | |
≥40 | 9 (28.1) | |
Race/Ethnicity | African American | 5 (15.6) |
Hispanic/Latino | 23 (71.9) | |
Caucasian or white | 3 (9.4) | |
Other * | 1 (3.13) | |
Comorbid conditions | Diabetes Mellitus | 10 (31.3) |
Hypertension ^ | 8 (25) | |
Asthma | 3 (9.4) | |
CKD | 1 (3.13) | |
Cancer | 1 (3.13) |
Lipid Parameters | Number (%) of Subjects Outside Reference Range | Mean | Median | Interquartile Range (25th–75th Percentile) | Reference Range |
---|---|---|---|---|---|
HDL-P | 29 (90.6) ↓ | 7 µmol/L | 6.4 µmol/L | 4.7–9.3 µmol/L | 15.2–27.5 µmol/L |
L-HDL-P | 2 (6.3) ↓ | 1 | 1.3 | 0.88–1.8 | 0.1–6.9 |
M-HDL-P | 12 (37.5) ↓ | 3 | 2.7 | 0.91–4.4 | 1.6–8.1 |
S-HDL-P | 30 (93.8) ↓ | 3 | 1.6 | 0.18–4.6 | 8.2–20.6 |
TRL-P | 14 (43.8) ↑ | 275 nmol/L | 277 nmol/L | 155–349 nmol/L | 19–291 nmol/L |
VL-TRL-P | 1 (3.1) ↑ | 0 | 0.03 | 0.001–0.15 | 0–0.7 |
L-TRL-P | 5 (15.6) ↑ | 8 | 3.64 | 0.063–8.06 | 0–11.9 |
M-TRL-P | 12 (37.5) ↓ | 25 | 11 | 0–31 | 0.4–70.7 |
S-TRL-P | 10 (31.3) ↑ | 79 | 69 | 25–116 | 0–103.6 |
VS-TRL-P | 11 (34.4) ↑ | 164 | 154 | 65–239 | 0–184.2 |
LDL-P | 4 (12.5) ↑ | 1890 nmol/L | 1800 nmol/L | 1397–2305 nmol/L | 851–2585 nmol/L |
L-LDL-P | 0 | 63 | 7.1 | 0–90 | 0–674 |
M-LDL-P | 0 | 61 | 0 | 0–35 | 0–1376 |
S-LDL-P | 14 (43.8) ↓ | 549 | 108 | 0–811 | 71–1865 |
LpZ particles | 25 (78.1) ↑ | 1217 nmol/L | 1280 nmol/L | 594–1907 nmol/L | 0 nmol/L |
LpX particles | 23 (72) ↑ | 149 mg/dL | 191 mg/dL | 0–253 mg/dL | 0 mg/dL |
Body Mass Index (Kg/m2) | Lipid Parameters | Mean | Median | Interquartile Range (25th–75th Percentile) | Reference Range |
---|---|---|---|---|---|
<25 (N = 3) | HDL-P | 13 µmol/L | 15.5 µmol/L | 10.4–16.4 µmol/L | 15.2–27.5 µmol/L |
L-HDL-P | 1 | 1.6 | 1.2–1.8 | 0.1–6.9 | |
M-HDL-P | 6 | 3.7 | 2.6–8.7 | 1.6–8.1 | |
S-HDL-P | 5 | 3 | 2.2–6.6 | 8.2–20.6 | |
TRL-P | 180 nmol/L | 157 nmol/L | 107–242 nmol/L | 19–291 nmol/L | |
VL-TRL-P | 0 | 0.1 | 0.1–0.4 | 0–0.7 | |
L-TRL-P | 3 | 3.9 | 2–5.1 | 0–11.9 | |
M-TRL-P | 18 | 21 | 10–27 | 0.4–70.7 | |
S-TRL-P | 45 | 63 | 34–65 | 0–103.6 | |
VS-TRL-P | 113 | 55 | 53–144 | 0–184.2 | |
LpZ particles | 394 nmol/L | 0 nmol/L | 0–592 nmol/L | 0 nmol/L | |
LpX particles | 0 mg/dL | 0 mg/dL | 0 mg/dL | 0 mg/dL | |
≥30 (N = 21) | HDL-P | 7 µmol/L | 6.92 µmol/L | 4.3–9.9 µmol/L | 15.2–27.5 µmol/L |
L-HDL-P | 2 | 1.4 | 0.99–1.9 | 0.1–6.9 | |
M-HDL-P | 2 | 1.61 | 0.62–4.1 | 1.6–8.1 | |
S-HDL-P | 3 | 2.73 | 0.06–6.5 | 8.2–20.6 | |
TRL-P | 278 nmol/L | 270.5 nmol/L | 166–346 nmol/L | 19–291 nmol/L | |
VL-TRL-P | 0 | 0.058 | 0.002–0.152 | 0–0.7 | |
L-TRL-P | 10 | 3.43 | 0.26–10.4 | 0–11.9 | |
M-TRL-P | 26 | 4.78 | 0–27.5 | 0.4–70.7 | |
S-TRL-P | 80 | 76.3 | 25.4–116 | 0–103.6 | |
VS-TRL-P | 162 | 151 | 67–228 | 0–184.2 | |
LpZ particles | 1268 nmol/L | 1378 nmol/L | 615–1991 nmol/L | 0 nmol/L | |
LpX particles | 131 mg/dL | 172 mg/dL | 2.89–247 mg/dL | 0 mg/dL |
Other Metabolites | Number (%) of Subjects Outside Reference Range | Mean (in µmol/L) | Median (in µmol/L) | Interquartile Range (25th–75th Percentile) (in µmol/L) | Reference Range (in µmol/L) |
---|---|---|---|---|---|
Acetone | 8 (25) ↓ | 68 | 33 | 13–50 | 11–127 |
Acetoacetate | 19 (59.4) ↓ | 19 | 18 | 12–28 | 21–130 |
BHB | 8 (25) ↑ | 447 | 235 | 132–400 | 40–396 |
Alanine | 23 (71.9) ↓ | 263 | 257 | 207–319 | 293–614 |
Leucine | 16 (50) ↑ | 246 | 243 | 220–285 | 122–245 |
Isoleucine | 7 (21.9) ↑ | 61 | 57 | 39–72 | 22–80 |
Valine | 8 (25) ↑ | 282 | 271 | 219–332 | 173–340 |
GlycA | 24 (75) ↑ | 710 | 713 | 571–819 | 312–569 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ballout, R.A.; Kong, H.; Sampson, M.; Otvos, J.D.; Cox, A.L.; Agbor-Enoh, S.; Remaley, A.T. The NIH Lipo-COVID Study: A Pilot NMR Investigation of Lipoprotein Subfractions and Other Metabolites in Patients with Severe COVID-19. Biomedicines 2021, 9, 1090. https://doi.org/10.3390/biomedicines9091090
Ballout RA, Kong H, Sampson M, Otvos JD, Cox AL, Agbor-Enoh S, Remaley AT. The NIH Lipo-COVID Study: A Pilot NMR Investigation of Lipoprotein Subfractions and Other Metabolites in Patients with Severe COVID-19. Biomedicines. 2021; 9(9):1090. https://doi.org/10.3390/biomedicines9091090
Chicago/Turabian StyleBallout, Rami A., Hyesik Kong, Maureen Sampson, James D. Otvos, Andrea L. Cox, Sean Agbor-Enoh, and Alan T. Remaley. 2021. "The NIH Lipo-COVID Study: A Pilot NMR Investigation of Lipoprotein Subfractions and Other Metabolites in Patients with Severe COVID-19" Biomedicines 9, no. 9: 1090. https://doi.org/10.3390/biomedicines9091090